...Founder and Chairman of Strategy Committee, Biocartis Group N.V., Former Founder, Chairman and CEO/CSO of Tibotec N.V....

...inhibitors (NRTIs) emtricitabine and tenofovir and the non-nucleoside reverse transcriptase inhibitor rilpivirine. Johnson & Johnson’s Tibotec...

...inhibitors (NRTIs) emtricitabine and tenofovir and the non-nucleoside reverse transcriptase inhibitor rilpivirine. Johnson & Johnson's Tibotec...

...in antiretroviral treatment-naïve adult patients with a viral load of <=100,000 copies/mL. Johnson & Johnson's Tibotec...

...data provided were not sufficient to recommend approval (see BioCentury, Aug. 5). Johnson & Johnson's Tibotec...

...said could increase the risk of resistance to Eviplera and similar treatments. Johnson & Johnson's Tibotec...

...were presented at the Drug Therapy in HIV Infection meeting in Glasgow. Johnson & Johnson's Tibotec...

...with product discovery and development out there," said Stoffels, who was CEO of virology company Tibotec-Virco...

...$22,000 for Complera. Gilead co-markets Atripla with Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.). The Tibotec...

...markets Prezista, a second-generation protease inhibitor. Last November, Gilead and the Janssen R&D Ireland (formerly Tibotec...